Outcomes and prognosis in advanced renal cell carcinoma

Matthew D. Galsky, Nicholas J. Vogelzang

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Breakthroughs in understanding the pathogenesis of renal cell carcinoma have led to recent therapeutic advances in this disease. However, the US FDA approval of sunitinib and sorafenib (and soon temsirolimus) after successful Phase III trials must also be attributed to the work of clinical investigators over the past decade defining the outcomes and major prognostic factors in patients with advanced renal cell carcinoma. Those past studies have been critical in providing a context for the interpretation of future trials with novel agents, optimizing patient selection for specific therapeutic approaches and identifying appropriate variables for patient stratification on randomized trials. This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma.

Original languageEnglish
Pages (from-to)839-845
Number of pages7
JournalExpert Review of Anticancer Therapy
Issue number6
StatePublished - Jun 2007
Externally publishedYes


  • Metastatic
  • Prognosis
  • Prognostic models
  • Renal neoplasm


Dive into the research topics of 'Outcomes and prognosis in advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this